Mesa Air Group Reports Third Quarter Fiscal 2025 Results and Provides Update on Proposed Merger with Republic Airways Holdings Inc. Management to Hold Call Following Market Close Today GlobeNewswire August 13, 2025 PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) — Mesa Air Group, Inc. (NASDAQ: MESA) (“Mesa” or the “Company”) today reported third quarter fiscal 2025 […]

OMNI-LITE INDUSTRIES REPORTS SECOND QUARTER FISCAL 2025 RESULTS CONFERENCE CALL FOR INVESTORS AUGUST 14, 2025, AT 4:00 PM EDT GlobeNewswire August 13, 2025 Second Quarter Fiscal 2025 Highlights Acquisition of eComp completed in April 2025 Revenue of US$3.5 million Adjusted EBITDA(1) of approximately US$95,000 Free Cash Flow(1) of approximately US$170,000 Strong cash balance of US$2.9

Vireo Growth Inc. Announces Second Quarter 2025 Results GlobeNewswire August 13, 2025 – Q2 GAAP revenue of $48.1 million increased 91% year-over-year, driven by recently-closed merger transactions – – Q2 pro forma financial results were in line with management's previously communicated expectations – – Recent $153 million refinancing positions Company with industry-leading cost of capital

Plug to Participate in the Canaccord Growth Conference GlobeNewswire August 13, 2025 SLINGERLANDS, N.Y., Aug. 13, 2025 (GLOBE NEWSWIRE) — Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the hydrogen economy, is participating today in the Canaccord Growth Conference in Boston, Massachusetts. Plug's participation underscores its leadership in the hydrogen

TeraWulf Reschedules Second Quarter 2025 Investor Conference Call to Thursday, August 14, 2025 Call to be held at 8:00 a.m. ET; webcast and replay information available on the Company's investor website at investors.terawulf.com GlobeNewswire August 13, 2025 EASTON, Md., Aug. 13, 2025 (GLOBE NEWSWIRE) — TeraWulf Inc. (Nasdaq: WULF) (“TeraWulf” or the “Company”), which owns

Immatics Announces Second Quarter 2025 Financial Results and Business Update GlobeNewswire August 13, 2025 Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: One-time infusion continues to show favorable tolerability as well as strong anti-tumor activity and durability in 33 heavily pretreated patients with metastatic melanoma in data from a Phase 1b trial presented at the 2025

PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update GlobeNewswire August 13, 2025 Multiple Abstracts Presented at the 2025 American Society of Clinical Oncology Annual Meeting Conference call and webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J., Aug. 13, 2025 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech”

ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights GlobeNewswire August 13, 2025 U.S. FDA Grants Fast Track Designation for PMN310 in Alzheimer's Disease, enhancing program's potential for priority review PRECISE-AD Phase 1b Trial in Alzheimer's Disease Progressing on Schedule: Over 50% enrolled, no cases of ARIA and no patient dropouts to date

BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. “HCW@Home” Series GlobeNewswire August 13, 2025 NEW HAVEN, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics, will participate in

Sanara MedTech Inc. Reports Second Quarter 2025 Financial Results (Unaudited) GlobeNewswire August 13, 2025 Net Revenue Increased 28% Year-Over-Year in Q2; Increased 27% Year-Over-Year in First Six Months of 2025 Announces Process to Evaluate Strategic Alternatives for its Tissue Health Plus, LLC Subsidiary FORT WORTH, TX, Aug. 13, 2025 (GLOBE NEWSWIRE) — Sanara MedTech Inc.